Rilvegostomig or Pembrolizumab for Non-Small Cell Lung Cancer
(ARTEMIDELung04 Trial)

Recruiting in Palo Alto (17 mi)

+87 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: AstraZeneca

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Eligibility Criteria

This trial is for individuals with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants should not have had prior treatments for their metastatic cancer.

Inclusion Criteria

Minimum life expectancy of 12 weeks

My organs and bone marrow are working well.

My lung cancer has been confirmed by lab tests.

+6 more

Exclusion Criteria

My brain metastases are stable, and I haven't needed steroids or seizure medicine for 4 weeks.

I do not have severe illnesses that would prevent me from following the study's requirements.

I have had an organ transplant.

+8 more

Participant Groups

The study is testing the effectiveness and safety of two drugs: Rilvegostomig and Pembrolizumab. Each participant will receive one of these as a first-line treatment to compare which works better.

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm AExperimental Treatment1 Intervention

Drug: rilvegostomig

Group II: Arm BActive Control1 Intervention

Drug: Pembrolizumab